Related Experiment Videos
Propranolol therapy for infantile hemangioma
Nivedita Gunturi1, Sriram Ramgopal, Subramanian Balagopal
1Department of Pediatrics, Sri Ramachandra University, Chennai, India.
Indian Pediatrics
|May 18, 2013
Summary
Propranolol shows promise for treating infantile hemangiomas (IH), potentially replacing steroids. While generally safe, careful administration is advised due to rare side effects, and recurrence is possible.
Area of Science:
- Pediatric dermatology
- Vascular anomalies
- Pharmacology
Background:
- Infantile hemangiomas (IH) are common vascular tumors in infants.
- Beta-blockers, including propranolol, are increasingly used for IH treatment.
- Corticosteroids have been a traditional treatment, but have side effects.
Purpose of the Study:
- To review existing literature on propranolol for infantile hemangioma treatment.
- To evaluate the efficacy and safety of propranolol in IH management.
- To compare propranolol with existing therapies like corticosteroids.
Main Methods:
- Literature search of PubMed for case reports, series, and trials.
- Inclusion of studies using keywords 'hemangioma' and 'propranolol'.
- Analysis of data on treatment outcomes and adverse events.
Main Results:
- Propranolol demonstrates efficacy across various IH locations (cutaneous, orbital, subglottic, hepatic) and ulcerated lesions.
- Improvement noted in PHACE syndrome patients.
- Favorable outcomes observed in non-responders to steroids, with no long-term adverse effects, though rare serious side effects (hypoglycemia, wheezing, hypotension, bradycardia) and recurrence are noted.
Conclusions:
- Propranolol shows potential as a first-line therapy or adjunct for IH.
- Further large-scale randomized controlled trials are needed to confirm safety and efficacy.
- Propranolol may offer an alternative to corticosteroids in IH management.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...